Outlook Therapeutics’ Bevacizumab Formulation Fails Primary Endpoint in nAMD Trial
ONS-5010 did not demonstrate non-inferior BCVA gains compared to ranibizumab at week 8 in the Phase III NORSE EIGHT trial. …
Protocol for Classifying and Monitoring AMD Patients
As recommended by the Clinical Director at Heidelberg Engineering, Christopher Mody Classification of AMD Classification of AMD falls into two…
popular posts
latest posts
